3 years ago

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Timothy P LaBranche, Lucian DiPietro, Natasja Brooijmans, Doug Wilson, Nicholas Lydon, Timothy Guzi, Kevin Wilson, Oleg Schmidt-Kittler, Michael C Heinrich, Yemarshet K Gebreyohannes, Joseph L Kim, Christoph Lengauer, Adam Shutes, Alexandra K Gardino, Nancy Kohl, Patrick Schöffski, Xing Julia Zhu, Alison Davis, Erica K Evans, Andy Boral, Yulian Zhang, Agnieszka Wozniak, Daniel J DeAngelo, Stephen Miller, Brian L Hodous, Beni Wolf
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an in-depth understanding of the disease-driving mutations combined with the ability to match these insights to tailored highly selective drugs. This rationale is presented for BLU-285, a clinical stage inhibitor of oncogenic KIT and PDGFRA alterations, including activation loop mutants that are ineffectively treated by current therapies. BLU-285, designed to preferentially interact with the active conformation of KIT and PDGFRA, potently inhibits activation loop mutants KIT D816V and PDGFRA D842V with subnanomolar potency and also inhibits other well-characterized disease-driving KIT mutants both in vitro and in vivo in preclinical models. Early clinical evaluation of BLU-285 in a phase 1 study has demonstrated marked activity in patients with diseases associated with KIT (aggressive systemic mastocytosis and gastrointestinal stromal tumor) and PDGFRA (gastrointestinal stromal tumor) activation loop mutations.

Publisher URL: http://doi.org/10.1126/scitranslmed.aao1690

DOI: 10.1126/scitranslmed.aao1690

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.